Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as INS1009
TPIP F2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TPIP Dose A | EXPERIMENTAL | Participants will receive single dose of TPIP F2 or F3 on Day 1 in treatment period 1 followed by single dose of TPIP F3 or F2 on Day 1 in treatment period 2. Both treatment periods are separated by 7-day washout period. |
| TPIP Dose B | EXPERIMENTAL | Participants will receive single dose of TPIP F2 or F3 on Day 1 in treatment period 1 followed by single dose of TPIP F3 or F2 on Day 1 in treatment period 2. Both treatment periods are separated by 7-day washout period. |
| TPIP Dose C | EXPERIMENTAL | Participants will receive single dose of TPIP F2 or F3 on Day 1 in treatment period 1 followed by single dose of TPIP F3 or F2 on Day 1 in treatment period 2. Both treatment periods are separated by 7-day washout period. |
| Name | Type | Description |
|---|---|---|
| TPIP F2 | DRUG | Inhalation using a capsule-based dry powder inhaler device. |
| TPIP F3 | DRUG | Inhalation using a capsule-based dry powder inhaler device. |
Inclusion Criteria * Body mass index (BMI): 18.0 to 32.0 kilogram per square metre (kg/m\^2), inclusive, at screening. * Weight: ≥50 kg (kilograms), inclusive, at screening. * Must be a nonsmoker (no use of tobacco or nicotine products) and/or has not used chewing tobacco for at least 1 month prior...
TPIP F2 is an investigational small molecule developed by Insmed Incorporated. It is a formulation of treprostinil palmitil inhalation powder, known as Formulation 2, designed for administration by inhalation. It has been studied in a Phase 1 clinical trial in healthy volunteers.
TPIP F2 is being developed by Insmed Incorporated, which trades on the Nasdaq under the ticker INSM. The company is the sponsor of the clinical program evaluating this inhaled formulation.
TPIP F2 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the program remains investigational rather than approved. No active trials of TPIP F2 are currently listed.
TPIP F2 has been evaluated in one completed Phase 1 trial, NCT07102316. The study assessed the relative bioavailability of a single inhalation administration of TPIP Formulation 2 compared with TPIP Formulation 3 in healthy participants. It enrolled 42 participants in the United States and was controlled and randomized.
TPIP F2 has been studied in healthy volunteers rather than in a patient population, so no therapeutic indication has been established for it. The completed Phase 1 trial, NCT07102316, evaluated relative bioavailability of the inhaled formulation in healthy participants aged 18 years and older.